clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kanayama N et al. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. 2007 Xenobiotica pmid:17484517
Altintas E et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. 2004 World J. Gastroenterol. pmid:15162544
Cindoruk M et al. Influence of H pylori on plasma ghrelin in patients without atrophic gastritis. 2007 World J. Gastroenterol. pmid:17461454
Mesquita MA et al. One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer. 2005 World J. Gastroenterol. pmid:15962376
Cosme A et al. Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. 2017 World J. Gastroenterol. pmid:28566898
Lai YC et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. 2003 World J. Gastroenterol. pmid:12854158
Choi HS et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22654429
Si JM et al. Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. 2005 World J. Gastroenterol. pmid:15948255
Hagiwara T et al. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. 2007 World J. Gastroenterol. pmid:17657838
Kawakami E et al. Furazolidone-based triple therapy for H pylori gastritis in children. 2006 World J. Gastroenterol. pmid:17006997
Sanches BS et al. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. 2016 World J. Gastroenterol. pmid:27672279
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Hwang JJ et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. 2015 World J. Gastroenterol. pmid:25945019
Ahmad N et al. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. 2009 World J. Gastroenterol. pmid:19575497
Luo XF et al. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. 2016 World J. Gastroenterol. pmid:27433095
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Sun QJ et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. 2010 World J. Gastroenterol. pmid:20976850
Chuah SK et al. A new look at anti-Helicobacter pylori therapy. 2011 World J. Gastroenterol. pmid:22046084
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Lee HJ et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. 2015 World J. Gastroenterol. pmid:25574111
Mamori S et al. Age-dependent eradication of Helicobacter pylori in Japanese patients. 2010 World J. Gastroenterol. pmid:20806435
Yoon JH et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. 2012 World J. Gastroenterol. pmid:23236238
Buzás GM and Józan J First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. 2006 World J. Gastroenterol. pmid:16981260
Babic Z et al. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. 2005 World J. Gastroenterol. pmid:15884110
Chen SJ et al. Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients. 2008 World J. Gastroenterol. pmid:18350632
Campuzano-Maya G Cure of alopecia areata after eradication of Helicobacter pylori: a new association? 2011 World J. Gastroenterol. pmid:21912461
Hao Q et al. New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China. 2004 World J. Gastroenterol. pmid:15052698
Abadi ATB Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. 2017 World J. Gastroenterol. pmid:29085187
Lai YC et al. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. 2004 World J. Gastroenterol. pmid:15052680
Molina-Infante J and Gisbert JP Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:25132750
Zhang L et al. Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. 2006 World J. Gastroenterol. pmid:16804982
Chang CC et al. Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils. 2005 World J. Gastroenterol. pmid:15742400
Feng LY et al. Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. 2005 World J. Gastroenterol. pmid:15742421
Aydemir S et al. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15682477
O'Morain C Role of Helicobacter pylori in functional dyspepsia. 2006 World J. Gastroenterol. pmid:16718752
Shimbo I et al. Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. 2005 World J. Gastroenterol. pmid:16437727
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Sun WH et al. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. 2005 World J. Gastroenterol. pmid:15832421
Wu IT et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. 2015 World J. Gastroenterol. pmid:26457027
Yilmaz O and Demiray E Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. 2007 World J. Gastroenterol. pmid:17278188
Chen KY et al. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. 2015 World J. Gastroenterol. pmid:26420970
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Wu JY et al. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. 2014 World J. Gastroenterol. pmid:24695835
Mabe K et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? 2009 World J. Gastroenterol. pmid:19750572
Riquelme A et al. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. 2007 World J. Gastroenterol. pmid:17589948
Ersoy O et al. H pylori infection in patients with Behcet's disease. 2007 World J. Gastroenterol. pmid:17589951